| Spherix is a biotechnology company seeking to develop small-molecule anti-cancer therapeutics. Co. owns the rights to patented technology from universities and researchers and it is in the process of developing therapeutic drugs through partnerships with educational institutions. Co.'s pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Co.'s AML and ALL compounds are targeted therapeutics designed to overcome various resistance mechanisms observed with the existing standard of care. DHA-dFdC, Co.'s pancreatic drug, is a compound poised to become the chemotherapy treatment for pancreatic cancer. The AIKI YTD return is shown above.
The YTD Return on the AIKI YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AIKI YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AIKI YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.